Skip to main content
See every side of every news story
Published • loading... • Updated

Moderna's RSV vaccine shown to provide strong protection against serious cases in adults 50 and older

Summary by Medical Xpress
A single dose of Moderna's mResvia RSV vaccine was 60.3% protective against documented respiratory syncytial virus (RSV) infections, 60.2% against RSV-associated emergency department or urgent care encounters and 81.8% against RSV-associated hospitalizations in a population of older U.S. veterans, according to a recent study in JAMA Network Open.

3 Articles

Lean Right

Moderna's new vaccine against respiratory syncytial virus (RSV), one of the leading causes of bronchiolitis, has shown strong protection against severe cases of infection among adults 50 years of age or older. The dose uses innovative messenger RNA (RNA) technology, adopted for the first time with the immunes against Covid-19. The vaccine, called mRESVIA, has already been approved by the United States Food and Drug Administration (FDA), a drug r…

·Rio de Janeiro, Brazil
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources are Center
67% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Medical Xpress broke the news in Douglas, United Kingdom on Thursday, November 12, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal